Alaproclate

From WikiMD.org
Jump to navigation Jump to search

Alaproclate

Alaproclate (pronounced: al-a-pro-clate) is a compound that was initially developed as an antidepressant by the pharmaceutical company AstraZeneca. However, during clinical trials, it was found to have serious side effects and its development was discontinued.

Etymology

The term "Alaproclate" is derived from the chemical name of the compound: Alanine proline claterate.

Pharmacology

Alaproclate acts as a serotonin reuptake inhibitor and glycine antagonist. It was initially developed for the treatment of depression and anxiety disorders. However, during phase II clinical trials, it was found to cause a high incidence of agranulocytosis, a serious blood disorder, leading to the discontinuation of its development.

Related Terms

  • Agranulocytosis: A condition characterized by a decrease in the number of white blood cells, leading to increased susceptibility to infections.
  • Serotonin: A neurotransmitter that contributes to feelings of well-being and happiness.
  • Glycine: An inhibitory neurotransmitter in the central nervous system, especially in the spinal cord.
  • Antidepressant: A medication used to treat major depressive disorder, anxiety disorders, or some chronic pain conditions.

See Also

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski